

Blueberry Therapeutics (Blueberry) today announced that it has started collaborating with the University of Manchester and University of Liverpool to explore development of a novel broad-spectrum antibiotic. This collaborative project brings together leading academics at the Universities of Manchester and Liverpool with Blueberry's drug discovery and development expertise and will explore the feasibility of a new approach for the treatment of Gram-negative bacterial infection. The collaboration is supported through a BBSRC Sparking Impact award made to the University of Manchester.

John Ridden, Chief Executive Officer at Blueberry Therapeutics said, "We are delighted to be working with world class experts from two of the UK's leading universities and excited about the potential for this collaboration to deliver new antibiotics. We see this as a wonderful example of how by working together we can tackle one of the major healthcare issues we currently face."

Professor Nigel Scrutton, Director of the Manchester Institute of Biotechnology said, "This is a major opportunity uniting the leading capabilities of Blueberry Therapeutics in antibiotic delivery with the expertise of the Manchester/Liverpool team in small molecule targeting of key bacterial enzyme targets"

Professor Ian Roberts, Professor of Microbiology and Associate Dean for Research Faculty of LifeSciences said, "This award represents a fantastic opportunity to develop an important collaboration between Blueberry Therapeutics and the Universities of Manchester and Liverpool in addressing the challenge of antibiotic resistance"

Dr Andrew Stachulski Senior Research Fellow, Department of Chemistry at the University of Liverpool said: "This is an excellent opportunity to revisit an important aspect of antibacterial research. Combining a new drug delivery concept with our earlier structural and synthetic knowledge will greatly advance this project"

ENDS

NOTES TO EDITORS

About Blueberry Therapeutics

Blueberry Therapeutics is an innovation driven Biopharmaceutical Company whose ambition is to take new therapeutic approaches that meet unmet medical needs in inflammatory and infection-associated conditions. Blueberry focus on preclinical research through to clinical proof of concept in both humans and companion animals eventually resulting in positive clinical proof of concepts which will be partnered with large or medium sized pharmaceutical companies for Phase III and marketing. Initially there are four areas of focus: bacterial Multi-Drug Resistant infections, Fungal Nail Infection, Atopic Dermatitis and Inflammatory Bowel Disease. For more information please visit: www.blueberrytherapeutics.com